Artiva Biotherapeutics (ARTV)

Executive Summary

Artiva Biotherapeutics is a clinical-stage biotechnology company advancing off-the-shelf, allogeneic natural killer (NK) cell therapies, with its lead candidate AlloNK® (AB-101) designed to enhance monoclonal antibody efficacy in autoimmune diseases and cancers. The company is publicly traded (NASDAQ: ARTV) with a valuation of approximately $247 million. Artiva's pipeline includes multiple Phase 1/2 trials targeting lupus nephritis, rheumatoid arthritis, and T-cell lymphoma, leveraging its proprietary allogeneic NK cell platform. Notably, the Phase 1 lupus nephritis trial (NCT06265220) and a Phase 1/2 rheumatoid arthritis trial (NCT06581562) are actively recruiting, while a Phase 2 trial in refractory rheumatoid arthritis (NCT06991114) began in 2025. In oncology, the company initiated a Phase 1 trial for GCC2005 in T-cell lymphoma (NCT06699771) in early 2025. Despite a withdrawn Phase 1/2 in breast/gastric cancer and a terminated Phase 2 in Hodgkin lymphoma, Artiva's focus on autoimmune indications and its allogeneic approach position it as a potential player in the cell therapy space, though early-stage data remain limited. The company's near-term value hinges on safety and efficacy readouts from its ongoing trials, particularly in lupus and rheumatoid arthritis, which represent large unmet medical needs.

Upcoming Catalysts (preview)

• Q3 2026AB-101 Phase 1 Lupus Nephritis Interim Data25% success
• Q4 2026GCC2005 Phase 1 T-Cell Lymphoma Interim Data25% success
• Q2 2026Potential Partnership or Licensing Deal for AlloNK Platform20% success